Cited by 610Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Open access

Paz-Ares, Luis, de Marinis, Filippo, Dediu, Mircea, Thomas, Michael, Pujol, Jean-Louis, Bidoli, Paolo, Molinier, Olivier, Sahoo, Tarini Prasad, Laack, Eckart, Reck, Martin, Corral, Jesús, Melemed, Symantha, John, William, Chouaki, Nadia, Zimmermann, Annamaria H, Visseren-Grul, Carla, Gridelli, Cesare·2012·The Lancet Oncology

DOI 10.1016/s1470-2045(12)70063-3

Open this paper in CoChat — free account

Abstract

Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC) benefit from pemetrexed maintenance therapy after induction therapy with a platinum-containing, non-pemetrexed doublet. The PARAMOUNT trial investigated whether continuation maintenance with pemetrexed improved progression-free survival after induction therapy with pemetrexed plus cisplatin.Methods In this double-blind, multicentre, phase 3, randomised placebo-controlled trial, patients with advanced non-squamous NSCLC aged 18 years or older, with no previous systemic chemotherapy for lung cancer, with at least one measurable lesion, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 participated. Before randomisation, patients entered an induction phase which consisted of four cycles of induction pemetrexed (500 mg/m(2)) plus cisplatin (75 mg/m(2)) on day 1 of a 21-day cycle. Patients who did not progress after completion of four cycles of induction and who had an ECOG performance status of 0 or 1 were stratified according to disease stage (IIIB or IV), ECOG performance status (0 or 1), and induction response (complete or partial response, or stable disease), and randomly assigned (2:1 ratio) to receive maintenance therapy with either pemetrexed (500 mg/m(2) every 21 days) plus best supportive care or placebo plus best supportive care until disease progression. Randomisation was done with the Pocock and Simon minimisation method. Patients and investigators were masked to treatment assignment. The primary endpoint was progression-free survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT00789373.Findings Of the 1022 patients enrolled, 939 participated in the induction phase. Of these, 539 patients were randomly assigned to receive continuation maintenance with pemetrexed plus best supportive care (n=359) or with placebo plus best supportive care (n=180). Among the 359 patients randomised to continuation maintenance with pemetrexed, there was a significant reduction in the risk of disease progression over the placebo group (HR 0·62, 95% CI 0·49-0·79; p<0·0001). The median progression-free survival, measured from randomisation, was 4·1 months (95% CI 3·2-4·6) for pemetrexed and 2·8 months (2·6-3·1) for placebo. Possibly treatment-related laboratory grade 3-4 adverse events were more common in the pemetrexed group (33 [9%] of 359 patients) than in the placebo group (one [<1%] of 180 patients; p<0·0001), as were non-laboratory grade 3-5 adverse events (32 [9%] of 359 patients in the pemetrexed group; eight [4%] of 180 patients in the placebo group; p=0·080); one possibly treatment-related death was reported in each group. The most common adverse events of grade 3-4 in the pemetrexed group were anaemia (16 [4%] of 359 patients), neutropenia (13 [4%]), and fatigue (15 [4%]). In the placebo group, these adverse events were less common: anaemia (one [<1%] of 180 patients), neutropenia (none), and fatigue (one <1%]). The most frequent serious adverse events were anaemia (eight [2%] of 359 patients in the pemetrexed group vs none in the placebo group) and febrile neutropenia (five [1%] vs none). Discontinuations due to drug-related adverse events occurred in 19 (5%) patients in the pemetrexed group and six (3%) patients in the placebo group.Interpretation Continuation maintenance with pemetrexed is an effective and well tolerated treatment option for patients with advanced non-squamous NSCLC with good performance status who have not progressed after induction therapy with pemetrexed plus cisplatin.Funding Eli Lilly and Company.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(12)70063-3

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
AJCC Cancer Staging Manual
(2016) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,300
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Analysis of Binary Data
Cox, D. R. (2008) · Springer eBooks · doi:10.1007/978-0-387-32833-1_5 · Cited by 2,687
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Self-citation

Show all 33 references

Research works printed but not linked: 1

Ciuleanu, 2008, Impact of induction chemotherapy on the outcome of treatment with pemetrexed in patients with advanced non-small-cell lung cancer: a retrospective analysis of a phase III trial, Ann Oncol, 19, viii98

Sorted by citations

Items 101–200 of 607

Histologic Classification of Non-Small-Cell Lung Cancer over Time: Reducing the Rates of Not-Otherwise-Specified
Ho, C., Tong, K. M., Ramsden, K., Ionescu, D. N., & Laskin, J. J. (2015) · Current Oncology · doi:10.3747/co.22.2339 · Cited by 38
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Pujol, J.-L., Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Bidoli, P., Corral, J., Antonio, B. S., Chouaki, N., John, W. J., et al. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.06.007 · Cited by 39
Self-citation
Management of advanced lung cancer in resource-constrained settings: a perspective from India
Singh, N., Aggarwal, A. N., & Behera, D. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.119 · Cited by 39
Update on systemic therapy of advanced non-small-cell lung cancer
Čufer, T., & Knez, L. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.940327 · Cited by 37
Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)
Baggstrom, M. Q., Socinski, M. A., Wang, X. F., Gu, L., Stinchcombe, T. E., Edelman, M. J., Baker, S., Feliciano, J. L., Novotny, P. J., Hahn, O. M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.022 · Cited by 36
Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial
Wang, Q., Jiao, L., Wang, S., Chen, P., Bi, L., Zhou, D., Yao, J., Li, J., Chen, Z., Jia, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01233 · Cited by 35
Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada
Gotfrit, J., Shin, J., Mallick, R., Stewart, D. J., & Wheatley‐Price, P. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0314 · Cited by 38
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
O'Brien, M. E. R., Gaafar, R. M., Hasan, B., Menis, J., Čufer, T., Popat, S., Woll, P. J., Surmont, V. F. M., Georgoulias, V., Montes, A., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.04.026 · Cited by 37
An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Felip, E., Besse, B., von Pawel, J., Mellemgaard, A., Reck, M., Bosquée, L., CHOUAID, C., Barragán, P. L., Paul, E. M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000005 · Cited by 36
Self-citation
A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non–Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M. S., Neal, J. W., Adrouny, A., Cherry, A. M., & Wakelee, H. A. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.04.008 · Cited by 36
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study
Wu, Y.-L. L. C., Kim, J.-H., Park, K., Zaatar, A., Klingelschmitt, G., & Ng, C. S. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.012 · Cited by 36
Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small-Cell Lung Cancer
Romanus, D., Cardarella, S., Cutler, D., Landrum, M. B., Lindeman, N. I., & Gazelle, G. S. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000474 · Cited by 36
Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing
Doble, B., John, T., Thomas, D. M., FELLOWES, A. P., Fox, S. B., & Lorgelly, P. K. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.024 · Cited by 35
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study
Conley, B. A., Staudt, L., Takebe, N., Wheeler, D. A., Wang, L., Cardenas, M., Korchina, V., Zenklusen, J. C., McShane, L. M., Tricoli, J. V., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa061 · Cited by 36
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial
Kogure, Y., Iwasawa, S., Saka, H., Hamamoto, Y., Kada, A., Hashimoto, H., Atagi, S., Takiguchi, Y., Ebi, N., Inoue, A., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00255-5 · Cited by 38
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease
Zhou, C., Qin, Y., Zhao, W. M., Liang, Z., Li, M., Liu, D., Bai, L., Chen, Y., Chen, Y., Cheng, Y. S., et al. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-339 · Cited by 39
Oral Chinese Herbal Medicine as Maintenance Treatment after Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Wang, Q., Wang, Q., Wang, S., Jiao, L., Zhang, R. X., Zhong, Y., Zhang, J., & Xu, L. (2017) · Current Oncology · doi:10.3747/co.24.3561 · Cited by 35
Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer
Wu, Y.-L. L. C., Lü, S., Cheng, Y., Zhou, C., Wang, M., Qin, S., Lü, Y., Zhang, Y., Zhu, Y., Song, X., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.007 · Cited by 35
Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non–Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older
Battisti, N. M. L., Sehovic, M., & Extermann, M. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.03.005 · Cited by 34
Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study
Visser, S., Huisbrink, J., Veer, N. E. V. ‘., van Toor, J. J., van Boxem, A. J. M., van Walree, N. C., Stricker, B. H. C., & Aerts, J. G. J. V. (2018) · European Respiratory Journal · doi:10.1183/13993003.00884-2018 · Cited by 33
Chemotherapy Plus Best Supportive Care versus Best Supportive Care in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Zhong, C., Liu, H., Jiang, L., Zhang, W., & Yao, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058466 · Cited by 32
Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer
Karayama, M., Inui, N., Fujisawa, T., Enomoto, N., Nakamura, Y., Kuroishi, S., Yokomura, K., Koshimizu, N., Sato, M., Toyoshima, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.01.013 · Cited by 33
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219
Melosky, B. L., Bradbury, P. A., Tu, D., Florescu, M., Reiman, T., Nicholas, G. A., Basappa, N. S., Rothenstein, J. M., Goffin, J. R., Laurie, S. A., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.027 · Cited by 32
Cost-Effectiveness of Continuation Maintenance Pemetrexed After Cisplatin and Pemetrexed Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Estimates From the Perspective of the Chinese Health Care System
Zeng, X., Peng, L., Li, J., Chen, G., Tan, C., Wang, S., Wan, X., Ouyang, L., & Zhao, Z. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.12.013 · Cited by 32
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)
Zappa, F., Droege, C., Betticher, D. C., von Moos, R., Bubendorf, L., Ochsenbein, A. F., Gautschi, O. P., Leibundgut, E. O., Froesch, P., Stahel, R. A., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.08.017 · Cited by 31
The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.
Lwin, Z., Riess, J. W., & Gandara, D. R. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.08.47 · Cited by 31
Update in Lung Cancer and Mesothelioma 2012
Powell, C. A., Halmos, B., & Nana-Sinkam, S. P. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201304-0716up · Cited by 32
MicroRNA 25 , microRNA 145 , and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations
Shi, S., Wang, M., Tian, J., Li, R., Chang, C., & Qi, J.-L. (2015) · Translational research · doi:10.1016/j.trsl.2015.11.006 · Cited by 31
Economic Analysis of ALK Testing and Crizotinib Therapy for Advanced Non-Small-Cell Lung Cancer
Lu, S., Zhang, J., Ye, M., Wang, B., & Wu, B. Y. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0017 · Cited by 31
Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
Lü, S., Yu, Y., Fu, S., & Ren, H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205827 · Cited by 31
Pemetrexed for the treatment of non-small cell lung cancer
Genova, C., Rijavec, E., Truini, A., Coco, S., Sini, C., Barletta, G., Bello, M. G. D., Alama, A., Savarino, G., Pronzato, P., et al. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.802774 · Cited by 30
Implementation of supportive care and best supportive care interventions in clinical trials enrolling patients with cancer
Lee, R. T., Ramchandran, K. J., Sanft, T. B., & Roenn, J. V. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv207 · Cited by 31
New Concepts in the Treatment of Malignant Pleural Mesothelioma
Wald, O., & Sugarbaker, D. J. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-041316-085813 · Cited by 30
The End of Nihilism: Systemic Therapy of Advanced Non–Small Cell Lung Cancer
Ernani, V., Steuer, C. E., & Jahanzeb, M. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-102442 · Cited by 29
Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials
Ghatalia, P., Morgan, C. J., & Sonpavde, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.018 · Cited by 29
Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?
Deslypere, G., Gullentops, D., Wauters, E., & Vansteenkiste, J. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918772810 · Cited by 29
Clinicopathologic features of non-small cell lung cancer in India and correlation with epidermal growth factor receptor mutational status
Bhatt, A., Pai, R., Rebekah, G. J., Nehru, G., Dhananjayan, S., Samuel, A., Singh, A. K., Joel, A., Korula, A., & Chacko, R. (2013) · Indian Journal of Cancer · doi:10.4103/0019-509x.117016 · Cited by 28
Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089)
Rittmeyer, A., Горбунова, В. А., Vikström, A., Scherpereel, A., Kim, J.-H., Ahn, M., Chella, A., CHOUAID, C., Campbell, A., & Barlési, F. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a46bcf · Cited by 28
Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review
Karim, N. A., & Kelly, K. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0112 · Cited by 26
Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis
Zeng, X., Li, J., Peng, L., Wang, Y., Tan, C., Chen, G., Wan, X., Lu, Q., & Yi, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088881 · Cited by 26
PVM/MA-shelled selol nanocapsules promote cell cycle arrest in A549 lung adenocarcinoma cells
de Souza, L. R., Muehlmann, L. A., do Santos, M. S. C., Ganassin, R., Simón‐Vázquez, R., Joanitti, G. A., Mosiniewicz-Szablewska, E., Suchocki, P., Morais, P. C., González‐Fernández, Á., et al. (2014) · Journal of Nanobiotechnology · doi:10.1186/preaccept-5192989891337222 · Cited by 27
Association of Graded Folic Acid Supplementation and Total Plasma Homocysteine Levels With Hematological Toxicity During First-line Treatment of Nonsquamous NSCLC Patients With Pemetrexed-based Chemotherapy
Singh, N., Aggarwal, A. N., Kaur, J., & Behera, D. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000111 · Cited by 27
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
Zhang, J., Zhang, Y., Tang, S., Jiang, L., He, Q., Hamblin, L. T., He, J., Wu, J., Wu, J., Chen, Y., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-017240 · Cited by 27
Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer
Azizi, A. A., Lamarca, Á., & Valle, J. W. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.07.05 · Cited by 27
A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
Mubarak, N., Gaafar, R. M., Shehata, S., Hashem, T., Abigeres, D., Azim, H. A., El-Husseiny, G. A., Alhusaini, H., & Liu, Z. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-423 · Cited by 26
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer
Rossi, G., Alama, A., Genova, C., Rijavec, E., Tagliamento, M., Biello, F., Coco, S., Bello, M. G. D., Boccardo, S., & Grossi, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1536746 · Cited by 26
Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)
Zinner, R., Visseren‐Grul, C., Spigel, D. R., & Obasaju, C. K. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3219 · Cited by 25
Self-citation
Treatment algorithm in 2014 for advanced non-small cell lung cancer: Therapy selection by tumour histology and molecular biology
Manegold, C. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.08.008 · Cited by 26
Less Toxic Chemotherapy Improves Uptake of All Lines of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A 10-Year Retrospective Population-Based Review
Ho, C., Ramsden, K., Zhai, Y., Murray, N., Sun, S. B., Melosky, B. L., & Laskin, J. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000225 · Cited by 25
Novel systemic therapy against malignant pleural mesothelioma
Mancuso, M. R., & Neal, J. W. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.06.01 · Cited by 25
Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review
van der Weijst, L., Lievens, Y. N., Schrauwen, W., & Surmont, V. F. M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00715 · Cited by 25
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study
Niho, S., Yoshida, T., Akimoto, T., Sakamaki, K., Ono, A., Seto, T., Nishio, M., Yamamoto, N., Hida, T., Okamoto, H., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.01.008 · Cited by 25
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Frost, N., & Reck, M. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432524 · Cited by 25
Self-citation
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review
Kulkarni, S., Vella, E. T., Coakley, N., Cheng, S. Y.-S., Gregg, R. W., Ung, Y., & Ellis, P. M. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.007 · Cited by 24
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?
Frega, S., Maso, A. D., Ferro, A., Bonanno, L., Conte, P., & Pasello, G. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.03.012 · Cited by 25
Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients
Agulló-Ortuño, M. T., García‐Ruíz, I., Díaz-García, C. V., Enguita, A. B., Pardo, V., Prieto‐García, E., Ponce, S., Iglesias, L., Zugazagoitia, J., Lopez-Martin, J. A., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-04008-9 · Cited by 24
Self-citation
Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment: an EORTC-STBSG database study
Verschoor, A. J., Litière, S., Marreaud, S. I., Judson, I. R., Toulmonde, M., Wardelmann, E., Cesne, A. L., & Gelderblom, H. A. J. (2020) · Clinical Sarcoma Research · doi:10.1186/s13569-020-00137-5 · Cited by 24
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis
Sheng, L., Gao, J., Xu, Q., Zhang, X., Huang, M., Dai, X., Li, S., & Liu, L. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211018537 · Cited by 24
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials
Scagliotti, G. V., Gridelli, C., de Marinis, F., Thomas, M., Dediu, M., Pujol, J.-L., Manegold, C., Antonio, B. S., Peterson, P. M., John, W. J., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.005 · Cited by 24
Self-citation
Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer
Tamiya, A., Tamiya, M., Shiroyama, T., Kanazu, M., Hirooka, A., Tsuji, T., Morishita, N., Asami, K., Suzuki, H., Okamoto, N., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds544 · Cited by 24
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer
Ciuleanu, T., Socinski, M. A., Obasaju, C. K., Luft, A. V., Szczęsna, A., Szafrański, W., Ramlau, R., Bálint, B., Molinier, O., Depenbrock, H., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.10.004 · Cited by 24
Self-citation
Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis
Zhu, J., Li, T., Wang, X., Ye, M., Cai, J. Q., Xu, Y., & Wu, B. Y. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-39 · Cited by 22
The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China
Zhou, S., Song, B., Li, C., Tang, W., Zhang, X., Jin, X., Xu, X., Wang, Q., Zheng, H., & Fu, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-27824-9 · Cited by 23
Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer
Losanno, T., & Gridelli, C. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1170116 · Cited by 23
Self-citation
Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non–Small-cell Lung Cancer
Matikas, A., Kentepozidis, N. K., Georgoulias, V., & Kotsakis, A. P. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.006 · Cited by 24
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer
Yang, J. C., Mok, T. S. K., Han, B., Orlando, M., Puri, T., & Park, K. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.06.013 · Cited by 23
Textbook of Uncommon Cancer
(2012) · Wiley eBooks · doi:10.1002/9781118464557 · Cited by 23
First-Line Crizotinib in ALK-Positive Lung Cancer
Alkan, A., Köksoy, E. B., & Utkan, G. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1415973 · Cited by 23
Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting
Sztankay, M. J., Giesinger, J. M., Zabernigg, A. F., Krempler, E., Pall, G., Hilbe, W., Burghuber, O. C., Hochmair, M. J., Rumpold, G., Doering, S., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3543-7 · Cited by 22
SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013
Camps, C., Felip, E., García‐Campelo, R., Trigo, J. M., & Garrido, P. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1085-2 · Cited by 22
Identification of miR-124a as a novel diagnostic and prognostic biomarker in non-small cell lung cancer for chemotherapy
Luo, P., Yang, Q., Cong, L., Wang, X., Li, Y., Zhong, X., Xie, R., Jia, C., Yang, H., Li, W., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6595 · Cited by 21
Recommendations for supportive care and best supportive care in NCCN clinical practice guidelines for treatment of cancer: Differences between solid tumor and hematologic malignancy guidelines
Mo, L., Urbauer, D. L., Bruera, E. D., & Hui, D. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06245-2 · Cited by 21
Maintaining clarity: Review of maintenance therapy in non-small cell lung cancer
Dearing, K. R. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i2.103 · Cited by 22
Therapeutic management of ALK+nonsmall cell lung cancer patients
Duchemann, B., Friboulet, L., & Besse, B. (2015) · European Respiratory Journal · doi:10.1183/09031936.00236414 · Cited by 22
Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?
Polo, V., & Besse, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt529 · Cited by 21
Chemotherapy for Advanced Non-small Cell Lung Cancer
Dietrich, M. F., & Gerber, D. E. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_6 · Cited by 22
Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial
Park, C., Oh, I., Kim, K. S., Choi, Y.-D., Jang, T. W., Kim, Y.-S., Lee, K.-H., Shin, K. C., Jung, C. Y., Yang, S. H., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.01.002 · Cited by 21
The value of physical performance measurements alongside assessment of sarcopenia in predicting receipt and completion of planned treatment in non-small cell lung cancer: an observational exploratory study
Collins, J., Noble, S., Chester, J. D., Davies, H. E., Evans, W. D., Farewell, D. M., Lester, J. F., Parry, D., Pettit, R. J., & Byrne, A. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3821-6 · Cited by 21
Effects of the Combination of Gliotoxin and Adriamycin on the Adriamycin-Resistant Non-Small-Cell Lung Cancer A549 Cell Line
Hung, L. M., Song, Y., & Cho, S. K. (2018) · Marine Drugs · doi:10.3390/md16040105 · Cited by 21
Algorithm for the Treatment of Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer: An Evidence-Based Overview
Daaboul, N., Nicholas, G. A., & Laurie, S. A. (2018) · Current Oncology · doi:10.3747/co.25.3792 · Cited by 20
Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review
Carril-Ajuria, L., Martín-Soberón, M. C., de Velasco, G., Agarwal, N., & Castellano, D. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03882-2 · Cited by 20
Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC
Han, J., Ni, X., Ye, X., & Wei, Z. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s90528 · Cited by 22
The Efficacy and Safety of Standardized Allergen-Removed Rhus verniciflua Extract as Maintenance Therapy after First-Line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Lee, J. S., Chae, J., Lee, S., Kim, K., Eo, W. K., Kim, S., Choi, W.-C., & Cheon, S. H. (2013) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x13500523 · Cited by 20
New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
Niki, M., Yokoi, T., Kurata, T., & Nomura, S. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s138887 · Cited by 20
Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy
Zhou, S., Zuo, L., He, X., Pi, J., Jin, J., & Shi, Y. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12827 · Cited by 20
Cost-Utility Of Afatinib And Gefitinib As First-Line Treatment For EGFR -Mutated Advanced Non-Small-Cell Lung Cancer
Wang, H., Zeng, C., Li, X., Wang, Y., Li, X., & Ge, W. (2018) · Future Oncology · doi:10.2217/fon-2018-0692 · Cited by 20
Survival Implications of De Novo Versus Recurrent Metastatic Non–Small Cell Lung Cancer
Moore, S. M., Leung, B. O., Wu, J., & Ho, C. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000513 · Cited by 20
Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer
Sheng, L., Cui, X., Cheng, L., Chen, Y., & Du, X. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1440-8 · Cited by 20
A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials
Russo, C. D., Cappoli, N., & Navarra, P. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02895-z · Cited by 20
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting
Sassier, M., Dugué, A. E., Clarisse, B., Lesueur, P., Avrillon, V., Bizieux‐Thaminy, A., Auliac, J. B., Kaluzinski, L., Tillon, J., Robinet, G., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.05.005 · Cited by 19
A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer
Tamiya, M., Tamiya, A., Kaneda, H., Nakagawa, K., Yoh, K., Goto, K., Okamoto, H., Shimokawa, T., Abe, T., Tanaka, H., et al. (2015) · Medical Oncology · doi:10.1007/s12032-015-0715-7 · Cited by 19
TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer
Takeuchi, A., Oguri, T., Yamashita, Y., Sone, K., Fukuda, S., TAKAKUWA, O., Uemura, T., Maeno, K., Fukumitsu, K., Kanemitsu, Y., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12882 · Cited by 20
Sex Differences in Hazard Ratio During Drug Treatment of Non–small-cell Lung Cancer in Major Clinical Trials: A Focused Data Review and Meta-analysis
Wang, L., Cao, Y., Ren, M., Chen, A., Cui, J., Sun, D., & Gu, W. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.12.008 · Cited by 19
Cost-effectiveness of first-line induction and maintenance treatment sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S.
Kumar, G., Woods, B. S., Hess, L. M., Treat, J., Boye, M. E., Bryden, P. A., & Winfree, K. B. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.05.020 · Cited by 18
Maintenance therapy in non-small cell lung cancer
Genestreti, G., Battista, M. D., Cavallo, G., Bartolotti, M., & Brandes, A. A. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1052410 · Cited by 18
Chemotherapy and Targeted Therapeutics as Maintenance of Response in Advanced Non-Small Cell Lung Cancer
Johnson, M. L., & Patel, J. D. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.007 · Cited by 18
Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC)
Schmid‐Bindert, G. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0261-1 · Cited by 18
Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined “Complementary Lethality”
Rytelewski, M., Ferguson, P. J., Vareki, S. M., Figueredo, R., Vincent, M. D., & Koropatnick, J. D. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.7 · Cited by 18
Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study
Kawazoe, H., Yano, A., Ishida, Y., Takechi, K., Katayama, H., Ito, R., Yakushijin, Y., Moriguchi, T., Tanaka, M., Tanaka, A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171066 · Cited by 18
Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada
Vanderpuye-Orgle, J., Erim, D., Qian, Y., Boyne, D. J., Cheung, W. Y., Bebb, G. D., Shah, A., Pericleous, L., Maruszczak, M. J., & Brenner, D. R. (2022) · Oncology and Therapy · doi:10.1007/s40487-022-00187-3 · Cited by 17

Authors: Paz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., Corral, J., Melemed, S., John, W., Chouaki, N., Zimmermann, A. H., Visseren-Grul, C., & Gridelli, C.
Affiliations: Instituto de Biomedicina de Sevilla (ES)
Institutul Oncologic Bucuresti (RO)
Heidelberg University (DE)
Centre Hospitalier Universitaire de Montpellier (FR)
Azienda Ospedaliera San Gerardo (IT)
Centre Hospitalier du Mans (FR)
Jawaharlal Nehru Cancer Hospital and Research Centre (IN)
University Medical Center Hamburg-Eppendorf (DE)
LungenClinic Grosshansdorf (DE)
Eli Lilly (United States) (US)
Azienda Ospedaliera S.Giuseppe Moscati (IT)
Corresponding author: Paz-Ares, Luis
ORCID: Paz-Ares, Luis
Dediu, Mircea
Thomas, Michael
Pujol, Jean-Louis
Molinier, Olivier
Reck, Martin
Gridelli, Cesare
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2012-03
Volume: 13
Issue: 3
Pages: 247-255
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(12)70063-3
OpenAlex: W2005244154
Cited by: 610
References: 33
Citations by year: 2026: 9 · 2025: 9 · 2024: 18 · 2023: 15 · 2022: 23 · 2021: 37 · 2020: 38 · 2019: 40 · 2018: 47 · 2017: 63 · 2016: 44 · 2015: 72 · 2014: 67 · 2013: 80 · 2012: 46
FWCI: 68.37
Type: journal article
Language: en
Open access: green
www.sciencedirect.com
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion, cc-by-nc-nd)
Funders: Eli Lilly and Company
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: maintenance therapy, non-squamous non-small cell lung cancer, cisplatin, induction chemotherapy, progression-free survival, best supportive care, disease progression, platinum-based doublets, first-line therapy, ECOG performance status, neutropenia, febrile neutropenia
MeSH terms: Pemetrexed, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Double-Blind Method, Drug Administration Schedule, Europe, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Time Factors, Proportional Hazards Models, Treatment Outcome, Disease-Free Survival, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks